restor3d Reverse Total Shoulder Arthroplasty System
Restor3D · Decision date May 19, 2025
What did the FDA decide?
FDA records K243643 as a 510(k) premarket notification, with a decision dated May 19, 2025. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- May 19, 2025
Regulatory record facts
- Identifier
- K243643
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Restor3D
- Product code
- PHX
- Decision code
- SESE
- Decision date
- May 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Shoulder Prosthesis, Reverse Configuration.
FDA decision timeline
K243643 received
Application receipt date recorded by FDA.
K243643 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PHX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| FX Shoulder Solutions, Inc. | 510(k) clearance | Nov 5, 2026 | FDA | |
Veritas Shoulder SystemK263421 | restor3d Inc. | 510(k) clearance | Oct 22, 2026 | FDA |
| ENCORE MEDICAL, L.P. | 510(k) clearance | Oct 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Restor3D
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Durham, NC
Sources and methodology
- Original FDA record: K243643
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

